Latest Breaking News On - Sylvia wheeler - Page 8 : comparemela.com

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillanceApplication of the.

San diegoUnited statesSylvia wheelerAljanae reynoldsFrancesca baronePennsylvania centerSociety for immunotherapy of cancerGlobenewswire incCandel therapeutics incCompany or candel nasdaqDiscovery platformAdvanced analyticsAnnual meetingPeter takChief executive officerChief scientific officer

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma after experimental treatment with CAN-2409 Estimated overall.

United statesGroot koerkampGarrett nicholsAljanae reynoldsSylvia wheelerCompany nasdaqSociety for immunotherapyNational cancer instituteCandel therapeutics incProdrug plus chemoradiationBorderline resectableChief medical officerPaul peter takChief executive officerNon metastatic pancreaticEnd results

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

- Confirmed objective response rate of 40% in PD-L1 positive patients with no prior checkpoint inhibitor therapy - Median progression-free survival of 6.3 months in PD-L1 positive patients at.

San diegoUnited statesBrian wongAljanae reynoldsSylvia wheelerJulie brahmerExchange commissionSociety for immunotherapy of cancerTherapeutics incUpper aerodigestive departmentJohns hopkins universityAnnual meetingJohns hopkinsChief executive officerPrivate securities litigation reform act

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesGroot koerkampSylvia wheelerAljanae reynoldsGarrett nicholsCompany nasdaqSociety for immunotherapyCandel therapeutics incNational cancer instituteRandomized phaseNon metastatic pancreaticProdrug plus chemoradiationBorderline resectableChief medical officerPaul peter takChief executive officer

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Sylvia wheelerPiper sandlerAljanae reynoldsTherapeutics incSeveral upcoming investor conferencesHealthcare talksAnnualii conferencePharma conferenceAnnual healthcare conferenceAnnual evercore